John Spellman is an Executive Therapeutic Specialist at Gilead Sciences, where they focus on Hepatitis B and have received several accolades for their leadership and sales achievements, including the 2019 Letairis Market Leadership Award. With over 25 years of experience in pharmaceutical sales, they have a proven track record in various disease states and have successfully launched multiple products, such as Glucovance and Plavix, during their tenure at Bristol-Myers Squibb and Scios Inc. Additionally, John has excelled in training and developing sales representatives, demonstrating a commitment to teamwork and professional growth. They hold a Bachelor of Arts in Psychology from Rutgers University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices